Background: Peroxisome proliferator-activated receptor gamma (PPARg) is a key transcription factor in adipogenesis, and also regulates a number of genes associated with lipid storage and insulin sensitivity. Single nucleotide polymorphisms (SNPs) in the PPARG gene have been associated with obesity and diabetes. In this study, we explored the relationship of three PPARG gene variants with the metabolic syndrome (MetS) and related traits in a population from Bosnia and Herzegovina. Methods: Anthropometric and biochemical parameters were measured in 43 patients with MetS and 43 healthy controls. Subjects were genotyped for Pro12Ala (rs1801282) and 1431C>T (rs3856806) SNPs by classic PCR-restriction fragment length polymorphism analysis, and for -681C>G (rs10865710) variant by real-time PCR. Results: The genotype distributions for the three polymorphisms were not significantly different between MetS patients and controls. The Pro12Ala and 1431C>T variants were associated with lower body mass index in the control subjects (p=0.012 and p=0.049, respectively). In this group, the carriers of Pro12Ala had also lower waist circumference compared to the wild-type homozygotes (p=0.045).
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Kratak sadr`aj
Uvod: Peroksizomni proliferatorom aktivirani receptor gama (PPARg) predstavlja klju~ni transkripcijski faktor u adipogenezi, i reguli{e brojne gene povezane sa skladi{te -njem lipida i insulinskom osetljivo{}u. Pojedina~ni nukleotidni polimorfizmi PPARG gena povezani su s gojazno{}u i dijabetesom. U ovoj studiji, istra`ili smo povezanost tri varijante PPARG gena s metaboli~kim sindromom (MetS) i nje govim karakteristikama u populaciji Bosne i Herce govine. Metode: Antropometrijski i biohemijski parametri su iz me reni kod 43 pacijenta s MetS-om i 43 zdrava kontrolna subjekta. Po li morfizmi Pro12Ala (rs1801282) i 1431C>T (rs3856806) genotipizirani su klasi~nom PCR metodom pra}enom analizom polimorfizma du`ine restrikcijskih fragmenata (RFLP), a
Introduction
The metabolic syndrome (MetS) consists of several metabolic and physiological abnormalities, including abdominal obesity, dyslipidemia, impaired glucose homeostasis and hypertension. Over the last ten years, various criteria for the diagnosis of MetS have been proposed by several different organizations, and recently unified guidelines were finally accepted (1) . MetS is associated with 5-fold increased risk for type 2 diabetes and 2-fold increased risk for cardiovascular disease (2, 3) . MetS prevalence, in most countries, ranges between 20 and 30% in adults (2) . The most important etiological factors are low physical activity, excess calorie intake, aging and genetic factors (4) . The heritability of the MetS has been estimated to be about 30% (5).
Peroxisome proliferator-activated receptor gamma (PPARg), a nuclear hormone receptor, is a ligand-activated transcription factor that controls adipocyte differentiation and regulates a number of genes associated with energy homeostasis. PPARg upregulates the transcription of genes involved in free fatty acids trapping and triglyceride synthesis (6) . Activation of the receptor enhances insulin sensitivity by modifying the profile of adipokines secreted from adipose tissue and by favoring lipid accretion in, less hormonally sensitive, subcutaneous depots (6) . Rare loss-of-function mutations in the ligand-binding domain of human PPARG gene lead to partial lipodystrophy with severe insulin resistance, early-onset diabetes, dyslipidemia and hypertension (7) . The PPARG gene is located on chromosome 3p25, and is composed of nine exons (A1, A2, B and exons 1-6) and four promoters. Four different transcripts are produced by alternate promoter use and splicing (PPARG 1-4). PPARG1, PPARG3, and PPARG4 produce the same protein, while PPARG2 produces a protein with 30 additional amino acids at the N-terminus (8) . The most prevalent human PPARG gene variant is the Pro12Ala (p.P12A, rs1801282) polymorphism in exon B, with allelic frequency ranging between 2% and 23%, in different ethnic groups (9) . In vitro, the Pro12Ala variant exhibits reduced binding to DNA and modest impairment of transcriptional activation (10, 11) . Although early findings were inconsistent, replication studies and meta-analyses confirmed modest but significant increase in type 2 diabetes risk associated with the Pro allele (12) . However, the relationship of Pro12Ala variant with obesity, MetS and related traits is less defined (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) . Similarly, conflicting results were obtained regarding the association between met abolic phenotypes and another frequent variant, a silent mutation in exon 6 of the PPARG gene, 1431C>T (c.1431C>T, rs3856806) (13, 14, 16-18, 23, 24) . A recently discovered polymorphism in the PPARG3 promoter, located 5' of exon A2, -681C>G (c.-681C>G, rs10865710), was associated with lower promoter activity in vitro (25) . This is the first study conducted in subjects from Bosnia and Herzegovina in which we explored the relationship of three PPARG gene variants (Pro12Ala, 1431C>T, and -681C>G) with MetS and its features.
Materials and Methods

Subjects
A total of 86 subjects were enrolled in the study: 43 patients with the MetS, recruited from General Hospital Te{anj, Zenica-Doboj Canton, and 43 healthy controls. Each participant gave written informed consent. The study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Cantonal Hos pital Zenica and by the Institute for Genetic Engineering and Biotechnology, University of Sarajevo. MetS was diagnosed according to the harmonized definition from 2009 that includes presence of at least three of the following five criteria: increased waist circumference (≥94 cm in men or ≥80 cm in women), triglycerides ≥1.7 mmol/L (or specific treatment for this lipid abnormality), high-density lipoprotein cholesterol (HDL-cholesterol) <1.0 mmol/L in men or <1.3 mmol/L in women (or specific treatment for this lipid abnormality), blood pressure ≥130/85 mmHg (or treatment for previously diagnosed hypertension) and fasting glucose ≥5.6 mmol/L (or previously diagnosed type 2 diabetes) (1). Patients with an acute infection and/or inflammation, endocrine disorders, and those on insulin therapy were excluded from the study. The patients received antihypertensive (74% of all patients), hypoglycemic (58%) and hypolipidemic therapy (47%). A control group was comprised of 43 healthy, non-obese subjects who had less than three MetS components, and were not taking any medication.
Anthropometric and biochemical measurements
In all the subjects arterial blood pressure and anthropometric data (height, weight, and waist circumference) were measured. Waist circumference was measured at the midpoint between the lowest rib and the iliac crest (26) . Blood samples were drawn after an overnight fast. Serum glucose, total cholesConclusions: Results of our preliminary study indicate a beneficial effect of a common Pro12Ala variant on the metabolic phenotype in healthy non-obese subjects.
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Klju~ne re~i: gojaznost, insulinska rezistencija, metaboli~ki sindrom, peroksizomni proliferatorom aktivirani receptor gama (PPARg), polimorfizam, geneti~ki terol, HDL-cholesterol, low-density lipoprotein cholesterol (LDL-cholesterol), triglycerides and C-reactive protein (CRP) were determined by standard procedures with an autoanalyzer VITROS 350 Chemistry System (Ortho-Clinical Diagnostic, Rochester, New York, USA). Se rum insulin was measured by the immunoenzymometric assay on an AxSYM analyzer (Abbott Laboratories, Abbott Park, IL, USA). Glycohemo globin (HbA 1c ) was determined in the whole blood with EDTA by a NGSP-certified affinity separation method, using the NycoCard reader (AxisShield, Oslo, Norway). To assess insulin resistance, the homeostasis model assessment insulin resistance index (HOMA-IR) was calculated according to the formula: fasting insulin (mU/L) x fasting glucose (mmol/L) /22.5 (27) .
Genotyping
Genomic DNA was extracted from the whole blood using Miller's protocol (28) . Single nucleotide polymorphisms (SNPs), Pro12Ala and 1431C>T, were analyzed by classic PCR followed by restriction fragment length polymorphism (RFLP) analysis. Pro12Ala variant was genotyped using forward primer F: 5'CAAGCCCAGTCCTTTCTGTG-3', and a mismatch reverse primer R: 5'-AGCTATGACCAGTGA -AGGAATCGCTTTCCG-3', which introduced a restriction site in the wild-type allele (29) . For 1431C>T, F: 5'-CAGGTTTGCTGAATGTGAAGC-3' and R: 5'-TGGCTCAGGACTCTCTGCTAGT-3' pri mers were used. The amplified PCR products containing Pro12Ala (247 bp) and 1431C>T (259 bp) SNPs were digested with HpaII and NlaIII restriction enzymes, respectively, at 37 °C overnight. Restriction fragments were analyzed by 3% agarose gel electrophoresis.
SNP -681C>G was genotyped by hydrolysis probes real-time PCR using TaqMan® SNP Genotyping Assay (Applied Biosystems), ID C_938 4417_10. Real-time PCR was performed on the ABI PRISM™ 7700 Sequence Detection System (Applied Biosystems).
Genotyping was repeated for fifty percent of all samples (including all mutant homozygous and all heterozygous samples for Pro12Ala and 1431C>T SNPs and randomly selected other samples) with 100% reproducibility.
Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics version 19 software. Statistical significance was set as p<0.05. The differences in genotype frequencies between cases and controls were assessed by chi-square (c 2 ) test and Fisher's exact test (in the case where frequencies were less or equal to 5). Genotype and diplotype associations with clinical and biochemical markers were tested by Mann-Whitney test and Kruskal-Wallis test, respectively. Lin kage disequilibrium (LD) between polymorphisms was calculated by 2LD program (30) . Haplotype analyses were performed using PHASE 2.1 software (31).
Results
The characteristics of MetS patients and control subjects are presented in Table I . Values of all the measured traits were significantly different between cases and controls, except for total and LDL-cholesterol concentrations.
Genotype and mutant allele frequencies for Pro12Ala, 1431C>T, and -681C>G polymorphisms are shown in Table II . Genotype frequencies for all three SNPs were in line with the Hardy-Weinberg equilibrium in the control group (p>0.05). There were no significant differences in the distribution of genotypes for the three PPARG gene variants between MetS patients and controls (Table II) .
We also explored the relationship between genotypes and anthropometric, clinical, and biochemical features. In MetS patients group, the carriers of Pro12Ala polymorphism had higher HbA 1c levels compared to the wild-type homozygotes (p=0.016) ( Table III) . Significant associations with the measures of obesity (BMI and waist circumference) were not detected in the patients (Table III) .
In the control subjects, the Pro12Ala variant was significantly associated with lower BMI (p=0.012) and lower waist circumference (p=0.045) ( Table IV) . It also showed a trend of association with lower total and LDL-cholesterol levels (p=0.060 and p=0.070, respectively). Likewise, the carriers of 1431C>T polymorphism had lower BMI compared to the wild-type homozygotes (p=0.049). Significant associations with the other parameters were not found (Table IV) .
Two PPARG gene polymorphisms, 1431C>T and -681C>G, were in strong linkage disequilibrium (D'=0.94). The Pro12Ala variant was in LD at 75% with these two SNPs. We also performed haplotype analysis. Table V shows haplotype frequencies and diplotypes, with the following order of the three polymorphisms: -681C>G, Pro12Ala, and 1431C>T. There was no significant difference in the distribution of haplotypes between MetS patients and controls (p=0.64). Further, we explored the association between diplotypes and MetS-related quantitative traits. Since other diplotypes were rare, we tested the differences only between the complete wild-type diplotype, CProC/CProC, and two groups of combined diplotypes: a group of diplotypes with mutated -681C>G locus (CProC/GProC and GProC/GProC) and a group of diplotypes containing the haplotype with all three loci mutated, X/GAlaT (CProC/GAlaT, CAlaC/GAlaT, GProC/GAlaT, GProT/GAlaT and GAlaT/GAlaT). No significant associations in MetS group were found. In controls, individuals with X/GAlaT diplotype, compared to the CProC/CProC carriers, had significantly lower BMI (data presented as median (interquartile range): 21.5 (20.7-24.5) kg/m 2 vs. 25.3 (22.7-29.0) kg/m 2 ; p=0.023). However, the BMI difference was not significant after applying Bonferroni's correction for multiple comparisons (corrected level of significance a=0.017).
Discussion
The PPARG gene is implicated in adipocyte differentiation, obesity, dyslipidemia and insulin resistance, thus representing a good candidate gene for the MetS. This was the first study to examine the effect of PPARG gene variations on the MetS and its components in a population from Bosnia and Herzegovina. We found no relationship between the Pro12Ala, 1431C>T, and -681C>G polymorphisms and the MetS. Thus far, few studies have found an association of PPARG variants with an increased risk for MetS (21, 32) , while others, in line with our results, revealed no significant associations (15) (16) (17) 33) . Nevertheless, a large cohort study among nondiabetic Danish subjects found a decreased risk of insulin resistance syndrome associated with the Ala/Ala genotype (34) . Our preliminary study, however, had limited power to detect possibly small effects of the investigated SNPs on the MetS, due to the insufficient sample size. In general, inconsistent findings between genetic association studies might be attributed to inadequate statistical power. According to a recent meta-analysis, the combined overall odds ratio for an association between the Pro allele of Pro12Ala variant and type 2 diabetes was 1.16 (12) . A sample size of nearly 4000 patients, and the same number of controls, would be needed to detect this small effect size with 80% power. In addition, the MetS represents a very complex and heterogeneous disease, which could further compromise the results of genetic association studies (35) .
In the analysis of MetS-related quantitative traits according to different genotypes, the only significant association in the MetS patient group was found between the Pro12Ala variant and higher HbA 1c levels. However, the majority of patients in our study received oral hypoglycemic therapy, and this result has to be taken very cautiously. In the control group, Pro12Ala and 1431C>T SNPs demonstrated significant associations with lower BMI. In controls, carriers of Pro12Ala had also lower waist circumference compared to the wild-type homozygotes. A similar beneficial effect of the Pro12Ala variant on BMI was shown in a previous study of our group, done on Slovene patients with the polycystic ovary syndrome (23) . Asso ciations of the 681C>G variant with MetSrelated traits were not found in either group of subjects.
328 Duji} et al.: PPARG polymorphisms and the metabolic syndrome Only a few studies have examined the effect of -681C>G polymorphism on the metabolic phenotype. Results from these studies have demonstrated an association of -681C>G with higher LDL-cholesterol concentrations and body weight in a French population (25, 36) . The lack of association in our study might be attributed to the small sample size. On the other hand, a number of studies have explored the relationship of Pro12Ala and 1431C>T with obesity and MetS parameters, with conflicting results. Deeb et al. initially reported an association of Pro12Ala with lower BMI and improved insulin sensitivity in normal weight and slightly overweight Finns (10) . In the later study, Pro12Ala and 1431C>T SNPs were associated with increased BMI in obese Finn women (37) . In a cohort of Danish men, the Ala/Ala genotype was associated with a higher BMI in obese, but lower BMI in lean subjects (38) . A large meta-analysis detected a significant association of the Pro12Ala variant with higher BMI only in subjects with a BMI above 27 kg/m 2 (39) . Another meta-analysis of data from non-diabetic subjects found an association of the Ala allele with greater BMI and greater insulin sensitivity only in selected subgroups, such as Caucasians and obese subjects (40) . Our results were partially in accordance with the mentioned studies, since we found an association of the two PPARG variants with lower BMI only in the group of healthy control non-obese subjects (median BMI 24.7 kg/m 2 ). Disparate effects of the Pro12Ala variant on BMI in obese and lean subjects may be explained by the gene-nutrient interaction. Luan et al. showed that a low dietary polyunsaturated/saturated fatty acids ratio is associated with a greater BMI in Ala12 carriers, but when this ratio is high, the opposite is found (41) . These observations are in line with the results from a large prospective study in a French population (42) and a study in Italian diabetic patients (43) . Two other studies reported opposite findings: total dietary fat intake was associated with higher BMI in Pro/Pro individuals, but not among Ala12 carriers in a French Canadian po pulation (44) and healthy American women (45) . Similar effects of diet on waist circumference (44) and plasma lipid concentrations (45) were observed. The discrepancy between the mentioned studies may be due to the difficulty of accurately assessing intake of specific types of dietary fat (45) . However, such evidence of the gene-environment interaction could, at least partially, explain the controversial effects of Pro12Ala and 1431C>T SNPs on BMI.
The Pro12Ala polymorphism modulates transcriptional activity (10, 11) and leads to the less efficient stimulation of PPARG target genes. Protective effect of the Ala allele in type 2 diabetes is associated with improved insulin sensitivity (10, 12, 40, 46) . It has been shown that moderate reduction of PPARg activity in heterozygous PPARg-deficient mice decreases triglyceride content of white adipose tissue, skeletal muscle, and liver due to increased leptin expression and increase in fatty acid combustion and decrease in lipogenesis, thereby ameliorating high fat diet-induced obesity (47) . Decreased lipogenesis in white adipose tissue prevents adipocyte hypertrophy, which is associated with alleviation of insulin resistance, presumably due to decreases in free fatty acids, tumor necrosis factor a, and upregulation of adiponectin (47) . In our preliminary study, associations with markers of insulin resistance were not detected. However, we observed a trend of association of the Pro12Ala variant with lower total and LDLcholesterol levels in the control subjects. Previous studies that analyzed the association of Pro12Ala with blood lipids have reported opposing results. Only a few studies detected an association of the Ala allele with lower total cholesterol (18, 48) , and lower LDLcholesterol levels (48) . However, it has been more frequently associated with lower triglyceride (10, 34, 49-51) and higher HDL-cholesterol levels (10, 18, 51) , which has been confirmed by a recent metaanalysis (52) . As decreased HDL-cholesterol and increased triglyceride levels represent two components of the MetS, these findings support the hypothesis that the Pro allele may be one of the genetic factors that contribute to the MetS.
In the present study, we also showed an association of the 1431C>T variant with lower BMI in controls. This could be a consequence of the linkage disequilibrium between 1431C>T and Pro12Ala, or another polymorphism. Nevertheless, positive effects of this SNP on the metabolic phenotype have been demonstrated earlier. It has been associated with a favorable lipid profile (24, 33, 53) , and reduced risk of coronary artery disease (54) and severe atherogenesis (24) .
Our data showed that three PPARG gene SNPs were in high linkage disequilibrium, similarly as in a previous study (32) . Haplotype analysis confirmed the beneficial effect of mutated GAlaT haplotype on BMI in controls, although the significance was lost after multiple testing correction.
In conclusion, we found a significant association of Pro12Ala and 1431C>T polymorphisms with lower BMI in the control subjects. The Pro12Ala variant was also associated with lower waist circumference in controls. Associations of the investigated polymorphisms with markers of insulin resistance were not detected. Findings of our preliminary study indicate a beneficial effect of the common Pro12Ala variant on the metabolic phenotype in healthy non-obese subjects. Future, larger population-based studies are needed to clarify the role of this and other PPARG gene variants in MetS risk.
